睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
  2. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06956001,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Not used for biopsy during screening

    入选标准第 5 条

    Histologically/cytologically confirmed non-squamous NSCLC, classified as:

    入选标准第 6 条

  3. Metastatic (Stage IV) (Based on UICC/AJCC 8th edition TNM staging)

    入选标准第 8 条

  4. Allowed if: Prior (neo)adjuvant/definitive chemoradiotherapy completed ≥12 months before recurrence/progression

    入选标准第 14 条

    >30 Gy thoracic radiotherapy within 6 months or non-thoracic radiotherapy within 4 weeks prior to first dose (brain radiotherapy exceptions per Inclusion Criterion #12).

    排除标准第 5 条

    Major trauma/surgery within 4 weeks prior to treatment initiation.

    排除标准第 10 条

    Residual toxicity >Grade 1 (per NCI CTCAE v5.0) from prior anticancer therapy (except alopecia/neuropathy).

    排除标准第 29 条

  5. ECOG performance status 0-1.

    入选标准第 15 条

  6. Central lab-confirmed EGFR PACC or L861Q mutation (If tumor tissue is unavailable due to inaccessible lesions, sponsor consultation is required.)

    入选标准第 12 条

  7. At least one measurable lesion per RECIST v1.1, meeting the following:

    入选标准第 3 条

  8. Other malignancies cured by radical therapy ≥3 years prior

    排除标准第 32 条

  9. Pregnancy/lactation or planned pregnancy within 6 months post-treatment.

    排除标准第 33 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06956001,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent form (ICF).
  2. Age ≥18 years at the time of ICF signing.
  3. At least one measurable lesion per RECIST v1.1, meeting the following:
  4. No prior local therapy (e.g., radiotherapy)
  5. Not used for biopsy during screening
  6. Histologically/cytologically confirmed non-squamous NSCLC, classified as:
  7. Locally advanced (Stage IIIB/IIIC, unsuitable for curative surgery and/or definitive chemoradiotherapy)
  8. Metastatic (Stage IV) (Based on UICC/AJCC 8th edition TNM staging)
  9. Agreement to provide:
  10. Recent tumor tissue (from untreated lesions)
  11. Blood samples
  12. Central lab-confirmed EGFR PACC or L861Q mutation (If tumor tissue is unavailable due to inaccessible lesions, sponsor consultation is required.)
  13. No prior systemic therapy for advanced/metastatic NSCLC.
  14. Allowed if: Prior (neo)adjuvant/definitive chemoradiotherapy completed ≥12 months before recurrence/progression
  15. ECOG performance status 0-1.
  16. Life expectancy ≥12 weeks.
  17. Adequate bone marrow/organ function within 14 days before treatment (no transfusion/G-CSF within 2 weeks prior).
  18. Women of childbearing potential (WOCBP):
  19. Abstinence or contraception use
  20. No egg donation
  21. Non-sterilized males:
  22. Abstinence or contraception use
  23. No sperm donation
  24. CNS metastases allowed if protocol-specified criteria are met.

排除标准:Exclusion Criteria:

  1. Histologically/cytologically confirmed tumor with >10% neuroendocrine carcinoma, sarcomatoid carcinoma, or squamous cell components.
  2. Known ALK-positive, ROS1-positive, RET fusion-positive, NTRK fusion-positive, BRAF V600E mutation, MET exon 14 skipping mutation, or other targetable alterations with approved therapies.
  3. Prior treatments including:
  4. Systemic anti-tumor therapy for advanced/metastatic NSCLC (e.g., chemotherapy/targeted/immunotherapy). Neoadjuvant/adjuvant therapy exceptions per Inclusion Criterion #6.
  5. >30 Gy thoracic radiotherapy within 6 months or non-thoracic radiotherapy within 4 weeks prior to first dose (brain radiotherapy exceptions per Inclusion Criterion #12).
  6. Any prior EGFR-targeted therapy (including investigational EGFR-TKIs, mAbs, bispecific antibodies, etc.).
  7. Strong CYP3A4 inhibitors within 7 days or inducers within 21 days prior to first dose.
  8. Anticancer traditional Chinese medicines within 2 weeks prior to first dose.
  9. Non-specific immunomodulators (e.g., interferon, IL-2, thymosin) within 2 weeks prior to first dose.
  10. Major trauma/surgery within 4 weeks prior to treatment initiation.
  11. Clinically significant gastrointestinal abnormalities, including:
  12. Moderate/severe atrophic gastritis
  13. GI obstruction/perforation
  14. Chronic diarrhea/short bowel syndrome
  15. Major upper GI surgery (e.g., gastrectomy)
  16. Inflammatory bowel disease (Crohn's/ulcerative colitis) or active intestinal inflammation
  17. Inability to swallow tablets
  18. Uncontrolled systemic diseases.
  19. Severe acute/chronic infections.
  20. Interstitial lung disease (ILD)/non-infectious pneumonia:
  21. History requiring clinical intervention
  22. Current presence
  23. Suspicious imaging findings unresolved at screening
  24. Clinically significant cardiovascular dysfunction (active or history).
  25. Tumor invasion of critical adjacent structures (heart/esophagus/SVC etc.) with high bleeding/fistula risk. Exceptions may be considered if investigator assesses minimal risk.
  26. Pulmonary comorbidities causing severe impairment, including:
  27. Baseline lung diseases (e.g., pulmonary embolism [≤3 months], severe asthma/COPD/restrictive disease)
  28. Autoimmune/connective tissue disorders with pulmonary involvement (e.g., rheumatoid arthritis, sarcoidosis)
  29. Residual toxicity >Grade 1 (per NCI CTCAE v5.0) from prior anticancer therapy (except alopecia/neuropathy).
  30. Concurrent malignancies except:
  31. Cured localized skin cancers (BCC/SCC), superficial bladder cancer, cervical/breast DCIS, or papillary thyroid cancer
  32. Other malignancies cured by radical therapy ≥3 years prior
  33. Pregnancy/lactation or planned pregnancy within 6 months post-treatment.
  34. Inability to comply with study procedures/follow-up.
  35. Known hypersensitivity to furmonertinib or excipients.
  36. History of allergic reactions to pemetrexed/cisplatin/carboplatin.
  37. Other exclusionary per investigator judgment, including:
  38. Alcohol/drug abuse
  39. Severe comorbidities (including psychiatric) requiring treatment
  40. Critical laboratory abnormalities
  41. Social/familial factors compromising safety/data collection

引自 ClinicalTrials.gov, NCT06956001, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06956001,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06956001